Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Advances in Respiratory Medicine
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Author statement Editorial Policy and Information for Authors Reviewers 2019

open access

Vol 77, No 5 (2009)
ORIGINAL PAPERS
Published online: 2009-08-12
Submitted: 2013-02-22
View PDF Download PDF file
Get Citation

Prevalence of hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) in the population of adult asthmatics in Poland based on an epidemiological questionnaire

Łukasz Kasper, Krzysztof Sładek, Grażyna Bochenek, Mariusz Duplaga, Andrzej Szczeklik
Pneumonol Alergol Pol 2009;77(5):431-439.

open access

Vol 77, No 5 (2009)
ORIGINAL PAPERS
Published online: 2009-08-12
Submitted: 2013-02-22

Abstract


Introduction: Hypersensitivity reactions to drugs account for 25% of all side effects related to drugs, affecting more than 7% of the population. One in four such reactions is caused by acetylic acid and other non-steroidal anti-inflammatory drugs.
Material and methods: Between 1998 and 2000 epidemiological research was carried out in various centers, with the aim of estimating the frequency of allergy-based diseases in Poland. The objective of the study was to evaluate the frequency of hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), based on an epidemiological questionnaire, in the Polish adult population.
Results: Bronchial asthma was diagnosed in 582 patients (5.4%). Of that group, 75 patients (12.9%) additionally reported symptoms of hypersensitivity to NSAIDs. Aspirin-induced asthma was diagnosed in 11 patients (14.7%) with clinical manifestations of hypersensitivity responses. Frequency of aspirin-induced asthma with clinical symptoms amounted to 1.9% of asthmatics. In the assessment of severity of the disease, aspirin intolerance was the only statistically significant factor (p = 0.0003; odds ratio 28.6 with assumed 95% confidence interval).
Conclusions: In the population of adults in Poland, the frequency of aspirin-induced asthma amounted to 0.1%. Hypersensitivity to NSAIDs was observed in 12.9% of asthmatics. In asthmatics with symptoms of hypersensitivity to non-steroidal anti-inflammatory drugs, which takes the course of clinically demonstrable aspirin-induced asthma, the risk of severe asthma is 30-fold higher.

Abstract


Introduction: Hypersensitivity reactions to drugs account for 25% of all side effects related to drugs, affecting more than 7% of the population. One in four such reactions is caused by acetylic acid and other non-steroidal anti-inflammatory drugs.
Material and methods: Between 1998 and 2000 epidemiological research was carried out in various centers, with the aim of estimating the frequency of allergy-based diseases in Poland. The objective of the study was to evaluate the frequency of hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), based on an epidemiological questionnaire, in the Polish adult population.
Results: Bronchial asthma was diagnosed in 582 patients (5.4%). Of that group, 75 patients (12.9%) additionally reported symptoms of hypersensitivity to NSAIDs. Aspirin-induced asthma was diagnosed in 11 patients (14.7%) with clinical manifestations of hypersensitivity responses. Frequency of aspirin-induced asthma with clinical symptoms amounted to 1.9% of asthmatics. In the assessment of severity of the disease, aspirin intolerance was the only statistically significant factor (p = 0.0003; odds ratio 28.6 with assumed 95% confidence interval).
Conclusions: In the population of adults in Poland, the frequency of aspirin-induced asthma amounted to 0.1%. Hypersensitivity to NSAIDs was observed in 12.9% of asthmatics. In asthmatics with symptoms of hypersensitivity to non-steroidal anti-inflammatory drugs, which takes the course of clinically demonstrable aspirin-induced asthma, the risk of severe asthma is 30-fold higher.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

asthma; prevalence; aspirin induced asthma; non-steroidal anti-inflammatory drugs; hypersensitivity

About this article
Title

Prevalence of hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) in the population of adult asthmatics in Poland based on an epidemiological questionnaire

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 5 (2009)

Pages

431-439

Published online

2009-08-12

Bibliographic record

Pneumonol Alergol Pol 2009;77(5):431-439.

Keywords

asthma
prevalence
aspirin induced asthma
non-steroidal anti-inflammatory drugs
hypersensitivity

Authors

Łukasz Kasper
Krzysztof Sładek
Grażyna Bochenek
Mariusz Duplaga
Andrzej Szczeklik

References (38)
  1. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005; 5(4): 309–316.
    PubMed
  2. Faich GA. Adverse-drug-reaction monitoring. N Engl J Med. 1986; 314(24): 1589–1592.
    CrossRefPubMed
  3. Johansson SG, Hourihane JO, Bousquet J, et al. EAACI (the European Academy of Allergology and Cinical Immunology) nomenclature task force. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001; 56(9): 813–824.
    PubMed
  4. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001; 87(3): 177–180.
    CrossRefPubMed
  5. Widal F, Abrami P, Lermoyez J. Anaphylaxie et idiosyncrasie. Press Medical. 1922; 30: 189–192.
  6. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968; 68(5): 975–983.
    PubMed
  7. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006; 118(4): 773–786.
    CrossRefPubMed
  8. Szczeklik A, Niżankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and others NSAIDS’. In: Kay AB, Kaplan AP, Bousquet J, Holt PG. ed. Allergy and allergic diseases. Blackwell Publ , London 2008: 1966–1980.
  9. Grzelewska-Rzymowska I, Szmidt M, Rożniecki J. Pokrzywka z nadwrażliwością na aspirynę; studium kliniczne. Pneumonol Alergol Pol. 1993; 61: 25–28.
  10. James J, Waris R. Chronic Urticaria: The Effect of Aspirin. British Journal of Dermatology. 1970; 82(2): 204–205.
    CrossRef
  11. Mastalerz L, Setkowicz M, Sanak M, et al. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004; 113(4): 771–775.
    CrossRefPubMed
  12. Zembowicz A, Mastalerz L, Setkowicz M, et al. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol. 2003; 139(12): 1577–1582.
    CrossRefPubMed
  13. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999; 28(4): 717–722.
    PubMed
  14. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002; 57(7): 569–574.
    PubMed
  15. Beasley R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The Lancet. 1998; 351(9111): 1225–1232.
    CrossRef
  16. Ellwood P, Asher MI, Beasley R, et al. ISAAC Steering Committee. The international study of asthma and allergies in childhood (ISAAC): phase three rationale and methods. Int J Tuberc Lung Dis. 2005; 9(1): 10–16.
    PubMed
  17. Asher MI, Keil U, Anderson HR, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995; 8(3): 483–491.
    PubMed
  18. Maziak W, Behrens T, Brasky TM, et al. Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Münster, Germany. Allergy. 2003; 58(7): 572–579.
    PubMed
  19. Peat JK, Haby M, Spijker J, et al. Prevalence of asthma in adults in Busselton, Western Australia. BMJ. 1992; 305(6865): 1326–1329.
    PubMed
  20. Burney P, Malmberg E, Chinn S, et al. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J Allergy Clin Immunol. 1997; 99(3): 314–322.
    PubMed
  21. Chinn S, Burney P, Jarvis D, et al. Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). European Respiratory Journal. 1997; 10(11): 2495–2501.
    CrossRef
  22. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). European Respiratory Journal. 1996; 9(4): 687–695.
    CrossRef
  23. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000; 16(3): 432–436.
    PubMed
  24. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis. 1992; 146(1): 76–81.
    CrossRefPubMed
  25. Picado C, Castillo JA, Montserrat JM, et al. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J. 1989; 2(2): 127–129.
    PubMed
  26. Małolepszy J, Liebhart J, Wojtyniak B, et al. Występowanie chorób alergicznych w Polsce. Alergia Astma Immunologia. 2000; 5(supl. 2): 163–169.
  27. Liebhart J, Malolepszy J, Wojtyniak B, et al. Polish Multicentre Study of Epidemiology of Allergic Diseases. Prevalence and risk factors for asthma in Poland: results from the PMSEAD study. J Investig Allergol Clin Immunol. 2007; 17(6): 367–374.
    PubMed
  28. Schubert B, Grosse Perdekamp MT, Pfeuffer P, et al. Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol. 2005; 15(3): 164–167.
    PubMed
  29. Kalyoncu AF, Karakaya G, Sahin AA, et al. Occurrence of allergic conditions in asthmatics with analgesic intolerance. Allergy. 1999; 54(5): 428–435.
    PubMed
  30. Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 2006; 29(2): 119–132.
    PubMed
  31. Langman MJ. Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum. Ital J Gastroenterol Hepatol. 1999; 31 Suppl 1: S2–S5.
    PubMed
  32. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol. 1999; 13(2): 119–122.
    PubMed
  33. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med. 2004; 117 Suppl 5A: 63S–71S.
    PubMed
  34. Kasper Ł, Sładek K, Bochenek G, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003; 58(10): 1064–1066.
    PubMed
  35. CHAFEE F, SETTIPANE G. Aspirin intolerance I. Frequency in an allergic population. Journal of Allergy and Clinical Immunology. 1974; 53(4): 193–199.
    CrossRef
  36. Settipane GA, Chafee FH, Klein DE. Aspirin intolerance. II. A prospective study in an atopic and normal population. J Allergy Clin Immunol. 1974; 53(4): 200–204.
    PubMed
  37. Giraldo B, Blumenthal MN, Spink WW. Aspirin intolerance and asthma. A clinical and immunological study. Ann Intern Med. 1969; 71(3): 479–496.
    PubMed
  38. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998; 12(5): 1209–1218.
    PubMed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl